Frontiers in Medicine, 2022 IntroductionPruritus is a major and burdensome symptom in atopic dermatitis (AD). The number of systemic treatments available for AD has increased recently, enabling improved patient relief.ObjectiveTo evaluate the effect of AD treatments on pruritus ...
Youna Rodriguez-Le Roy +5 more
doaj +1 more source
34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies [PDF]
, 2022 Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease. Two phase 3 studies (TRuE-AD1/TRuE-AD2) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment (IGA) score of 2/3, and 3%–20% affected body surface
Bissonnette, Robert +2 more
core +1 more source
Interleukin-31 as a Clinical Target for Pruritus Treatment
Frontiers in Medicine, 2021 In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic ...
Kenji Kabashima, Hiroyuki Irie
doaj +1 more source
Biological drugs in the treatment of atopic dermatitis : current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine [PDF]
, 2020 Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations.
Agnieszka Mastalerz-Migas +20 more
core +1 more source
Treatment of patients with chronic pruritus of unknown origin with dupilumab [PDF]
, 2021 BACKGROUND: Chronic pruritus of unknown origin (CPUO) is a highly debilitating disease that lacks effective treatments. This study explores a new therapeutic strategy with dupilumab.
Badic, Asima +3 more
core +2 more sources
Atopic dermatitis in skin of colour. Part 2:considerations in clinical presentation and treatment options [PDF]
, 2023 Recent advances in atopic dermatitis (AD) present the condition as a heterogeneous disease of distinct endotypes across ethnic groups. AD in people with skin of colour may appear psoriasiform, lichenoid, scaly or papular, with a violaceous colour and ...
Gan, Christian +3 more
core +1 more source
JID Innovations, 2023 Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj +1 more source
Clinical trials of antibody drugs in the treatments of atopic dermatitis [PDF]
, 2023 Atopic dermatitis (AD) is one of the most common, relapsing, chronic inflammatory skin disease, being regarded as a global health issue. Recent studies have shown that Th2 cell-mediated type 2 immunity plays a central role in AD.
Guihao Zhou, Ming Chu, Yueyao Huang
core +1 more source
Modern therapies in atopic dermatitis: biologics and small molecule drugs [PDF]
, 2020 Atopic dermatitis (AD) is a frequent, chronic remittent skin disease. The pathophysiology of AD has been increasingly understood within the last years, which may help to identify different endotypes suitable for defined therapies in the future. A patient-
Aikaterina Alexiou +5 more
core +1 more source
Dermatology and Therapy, 2023 Introduction Validated patient report tools for quantifying patient experiences of itch in prurigo nodularis (PN) are limited. This study aimed to evaluate the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item ...
Shawn G. Kwatra +8 more
doaj +1 more source